Los Angeles Biotechnology Network
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ June 10, 2023 ] Graduating senior lights the path for transfer students – through her award-winning research and mentoring Los Angeles Biotech News
  • [ June 10, 2023 ] Postdoctoral Scientist – Karsh Division of Gastroenterology and Hepatology – Part-Time – CEDARS-SINAI – Los Angeles, CA Los Angeles Biotech Jobs
  • [ June 10, 2023 ] Adcomm votes yes on Leqembi full OK; Merck brings first IRA lawsuit; Special: LGBTQ+ leaders; Best-paying biopharma jobs; and more Los Angeles Biotech News
  • [ June 10, 2023 ] Scientist, Cell Biology – Thermo Fisher Scientific – West Hills, CA Los Angeles Biotech Jobs
  • [ June 10, 2023 ] Security Officer – Biotechnology Company – Allied Universal® – Oceanside, CA Los Angeles Biotech Jobs
HomeLos Angeles Biotech NewsSTAT Plus: Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

STAT Plus: Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

June 5, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on STAT Plus: Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?
"Anything that has the potential to keep a biosimilar off the market longer necessarily has a cost implication," said patent attorney Alexandra Valenti.

Click to view original post

Previous

David Chang steps up to CEO spot at WuXi’s cell and gene therapy CDMO; David Meline is the new CFO at Moderna

Next

Opiant Pharmaceuticals Statement on U.S. District Court Decision

Follow/Subscribe

POST A JOB
Tweets by LABioNetwork

Copyright © 2021 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered